Trevena, Inc. (TRVN)
OTCMKTS · Delayed Price · Currency is USD
0.0110
0.00 (0.00%)
Jan 21, 2026, 9:30 AM EST
Trevena Revenue
Trevena had revenue of $283.00K in the quarter ending September 30, 2024, with 57.22% growth. This brings the company's revenue in the last twelve months to $546.00K, down -82.97% year-over-year. In the year 2023, Trevena had annual revenue of $3.13M.
Revenue (ttm)
546.00K
Revenue Growth
-82.97%
P/S Ratio
0.02
Revenue / Employee
23.74K
Employees
23
Market Cap
10.64K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.13M | 3.54M | - |
| Dec 31, 2022 | -418.00K | -985.00K | - |
| Dec 31, 2021 | 567.00K | -2.50M | -81.52% |
| Dec 31, 2020 | 3.07M | 3.04M | 9,800.00% |
| Dec 31, 2019 | 31.00K | -5.70M | -99.46% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ObsEva | 19.64M |
| Scorpius Holdings | 2.41M |
| GeneLink | 1.58M |
| Entia Biosciences | 265.47K |
| Navidea Biopharmaceuticals | 610.00 |
Trevena News
- 1 year ago - Trevena Reports Third Quarter 2024 Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Trevena receives Nasdaq delisting notification - Seeking Alpha
- 1 year ago - Trevena Announces Receipt of Nasdaq Delisting Notification - GlobeNewsWire
- 1 year ago - Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing - GlobeNewsWire
- 1 year ago - What's Going On With Neurological Disease Focused Trevena On Thursday? - Benzinga
- 1 year ago - Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models - GlobeNewsWire
- 1 year ago - Trevena Reports First Quarter 2024 Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update - GlobeNewsWire